Olaparib
BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2
VA Office of Research and DevelopmentSmall moleculePhase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 58/ 100
- Competitive Position
- 95/ 100
Competitive context
7 Active assets in the BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin VA Office of Research and Development | Phase 2 | BB |
Veliparib AbbVie | Phase 2 | BB |
Letrozole UNICANCER | Phase 3 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II University Health Network, Toronto | Phase 2/3 | BB |
Metformin Alliance for Clinical Trials in Oncology | Phase 3 | B |
View all 26 →
Same molecule, other indications
Olaparib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →